Ultra-Fast Test Screens for All Types of Cancer with Simple Blood Draw

Cancer can occur at any stage of life, irrespective of age, lifestyle, or genetic background, making early detection critical for effective treatment and better patient outcomes. This underscores a pressing need for improved diagnostic methods in the medical field. Current cancer detection methods face challenges such as limited availability of screening tests, lengthy result processing times, high costs, and invasive procedures. Now, a pioneering technology has been developed that facilitates the early detection of cancer, potentially as early as stage -1, and aids in guiding subsequent imaging tests.

Oncosure (Pompano Beach, FL, USA) has launched its innovative Rapid Cancer Screening Test, democratizing access to early cancer detection. This test, requiring only a single blood draw, is capable of screening for all cancer types, thereby providing reassurance to individuals. Oncosure's cutting-edge screening technology employs rapid in situ hybridization and DNA fluorescent probes to deliver comprehensive and accurate cancer screening. The technology combines a rapid SITU hybridization platform, DNA fluorescent probes for ploidy detection, and cost-effective density gradient and low sequential centrifugation methods to provide thorough screening for aneuploidy across all chromosomes.

Image: The Rapid Cancer Screening Test delivers results in just 2 hours, compared to the 2-3 weeks typical with other tests (Photo courtesy of Shutterstock)

The Oncosure test identifies oncosomes—tiny vesicles that are markers of cancer cells—across all types of cancer. Employing advanced fluorescent microscopy, the test ensures precise and actionable outcomes. It offers a swift and dependable method for detecting cancer at very early stages, even stage -1, providing results that are both fast and definitive within a few hours. This enables healthcare providers to make timely decisions. Additionally, the Oncosure test can be instrumental in monitoring the efficacy of ongoing cancer treatments and in providing early detection of cancer recurrence for those in remission, enhancing the chances for successful intervention.

"One blood draw, all cancers—this is the future of cancer screening," said Jason Andrews, Vice President of Oncosure. "Cancer doesn't wait for symptoms, and neither should you. Our test empowers everyone to screen for any type of cancer with a single, non-invasive test."

Related Links:
Oncosure